NO2021036I1 - Ofatumumab - Google Patents

Ofatumumab

Info

Publication number: NO2021036I1
Authority: NO; Norway
Prior art keywords: ofatumumab
Prior art date: 2007-07-06

Application number

NO2021036C

Other languages

English (en)

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-07-06

Filing date

2021-09-13

Publication date

2021-09-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40228991&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2021036(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2021-09-13 Application filed by Novartis Ag filed Critical Novartis Ag

2021-09-13 Publication of NO2021036I1 publication Critical patent/NO2021036I1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Dermatology (AREA)
Molecular Biology (AREA)
Virology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Pulmonology (AREA)
Hematology (AREA)
Neurology (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Mycology (AREA)
Microbiology (AREA)
Urology & Nephrology (AREA)
Communicable Diseases (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Transplantation (AREA)
Cardiology (AREA)

NO2021036C 2007-07-06 2021-09-13 Ofatumumab NO2021036I1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US94822007P	2007-07-06	2007-07-06
PCT/US2008/069125 WO2009009407A1 (en)	2007-07-06	2008-07-03	Antibody formulations

Publications (1)

Publication Number	Publication Date
NO2021036I1 true NO2021036I1 (no)	2021-09-13

Family

ID=40228991

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO15155712A NO2889310T3 (no)	2007-07-06	2008-07-03
NO2021036C NO2021036I1 (no)	2007-07-06	2021-09-13	Ofatumumab

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
NO15155712A NO2889310T3 (no)	2007-07-06	2008-07-03

Country Status (38)

Country	Link
US (2)	US20110020328A1 (no)
EP (2)	EP2170388B1 (no)
JP (1)	JP5529017B2 (no)
KR (2)	KR101670454B1 (no)
CN (1)	CN101820912B (no)
AR (2)	AR067455A1 (no)
AU (1)	AU2008275278B2 (no)
BR (2)	BR122020026978B1 (no)
CA (1)	CA2692681C (no)
CL (1)	CL2008001984A1 (no)
CO (1)	CO6270340A2 (no)
CR (1)	CR11249A (no)
CY (3)	CY1118419T1 (no)
DK (2)	DK2170388T3 (no)
DO (1)	DOP2010000001A (no)
EA (1)	EA017994B1 (no)
ES (2)	ES2610821T3 (no)
FR (1)	FR21C1040I1 (no)
HK (2)	HK1141979A1 (no)
HR (2)	HRP20170033T1 (no)
HU (3)	HUE038501T2 (no)
IL (1)	IL202950A (no)
JO (1)	JO3219B1 (no)
LT (3)	LT2889310T (no)
MA (1)	MA31471B1 (no)
MX (1)	MX2010000017A (no)
NO (2)	NO2889310T3 (no)
NZ (1)	NZ582250A (no)
PE (1)	PE20090738A1 (no)
PL (2)	PL2889310T3 (no)
PT (2)	PT2889310T (no)
SI (2)	SI2170388T1 (no)
TR (1)	TR201802928T4 (no)
TW (2)	TWI515204B (no)
UA (1)	UA107557C2 (no)
UY (1)	UY31210A1 (no)
WO (1)	WO2009009407A1 (no)
ZA (1)	ZA200909107B (no)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20160279239A1 (en)	2011-05-02	2016-09-29	Immunomedics, Inc.	Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US20160355591A1 (en)	2011-05-02	2016-12-08	Immunomedics, Inc.	Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
UA107557C2 (xx) *	2007-07-06	2015-01-26		Композиція антитіла офатумумабу
US20100189721A1 (en) *	2007-07-06	2010-07-29	Smithkline Beecham Corporation	Antibody formulations
JP2013520476A (ja)	2010-02-26	2013-06-06	ノヴォノルディスクアー／エス	安定な抗体含有組成物
KR101903931B1 (ko)	2010-03-01	2018-10-02	바이엘 헬스케어 엘엘씨	조직 인자 경로 억제제 (ｔｆｐｉ)에 대한 최적화된 모노클로날 항체
ES2993022T3 (en)	2010-05-28	2024-12-20	Novo Nordisk As	Stable multi-dose compositions comprising an antibody and a preservative
US20140044727A1 (en) *	2011-04-07	2014-02-13	Glaxosmithkline Llc	Formulations with reduced viscosity
UA116189C2 (uk)	2011-05-02	2018-02-26	Мілленніум Фармасьютікалз, Інк.	КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
CA2831572C (en)	2011-05-02	2019-11-26	Immunomedics, Inc.	Ultrafiltration concentration of allotype selected antibodies for small-volume administration
TWI698254B (zh) *	2011-05-02	2020-07-11	美商千禧製藥公司	抗-α4β7抗體之調配物
UY34105A (es)	2011-06-03	2012-07-31	Lg Life Sciences Ltd	Formulación líquida estable de etanercept
US9592297B2 (en)	2012-08-31	2017-03-14	Bayer Healthcare Llc	Antibody and protein formulations
CA3162739A1 (en) *	2013-03-12	2014-10-02	Primal Therapies, Inc.	Dental composition comprising chelator and base
EP2805730A1 (en) *	2013-05-21	2014-11-26	Bergen Teknologioverforing AS	Nitric oxide donor for the treatment of chronic fatigue syndrome
WO2015162504A1 (en)	2014-04-23	2015-10-29	Novartis Ag	Novel dosing and uses of ofatumumab
WO2016189491A1 (en) *	2015-05-28	2016-12-01	Glaxosmithkline Intellectual Property Development Limited	Novel formulation
AU2017213775A1 (en) *	2016-02-03	2018-08-16	Outlook Therapeutics, Inc.	Buffer formulations for enhanced antibody stability
HUE063625T2 (hu)	2016-08-15	2024-01-28	Novartis Ag	Kezelési rendek és eljárások szklerózis multiplex ofatumumab alkalmazásával történõ kezelésére
JPWO2018179138A1 (ja) *	2017-03-29	2020-02-06	持田製薬株式会社	抗体含有液体製剤
US10799597B2 (en)	2017-04-03	2020-10-13	Immunomedics, Inc.	Subcutaneous administration of antibody-drug conjugates for cancer therapy
US11845798B2 (en)	2017-05-02	2023-12-19	Merck Sharp & Dohme Llc	Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
JOP20190260A1 (ar)	2017-05-02	2019-10-31	Merck Sharp & Dohme	صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
CA3033195A1 (en) *	2018-02-09	2019-08-09	Ecolab Usa Inc.	Flowability testing systems and methods
CN118403156A (zh)	2019-09-11	2024-07-30	诺华股份有限公司	通过转换疗法治疗rms
JP2022548848A (ja)	2019-09-11	2022-11-22	ノバルティスアーゲー	オファツムマブ治療患者における多発性硬化症以外の状態の管理
CN112675126A (zh) *	2019-10-18	2021-04-20	百奥泰生物制药股份有限公司	抗cd20抗体制剂及其应用
AU2021253674A1 (en)	2020-04-09	2022-11-03	Novartis Ag	Ofatumumab for treating MS while maintaining serum IgG
JP7057954B2 (ja) *	2020-09-03	2022-04-21	国立大学法人大阪大学	改善された保存安定性を有するタンパク質含有液体製剤
KR20230170923A (ko)	2021-04-14	2023-12-19	노파르티스 아게	아시아인 환자들에서 ms 치료용 오파투무맙
IL310813A (en)	2021-08-16	2024-04-01	Novartis Ag	OFATUMUMAB for the treatment of multiple sclerosis in children
KR20230150203A (ko) *	2022-04-20	2023-10-30	주식회사 알토스바이오로직스	오크렐리주맙(Ocrelizumab)을 포함하는 약학적 조성물과 그의 용도
CN116712390B (zh) *	2023-08-04	2023-11-14	上海览屹医药科技有限公司	一种高浓度高稳定性的抗体制剂及其制备方法
WO2025037335A1 (en) *	2023-08-12	2025-02-20	Dr. Reddy's Laboratories Limited	Formulations of anti-cd20 antibody

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4816401A (en) *	1985-09-09	1989-03-28	University Of Rochester	Serum free cell culture medium
DE3920358A1 (de)	1989-06-22	1991-01-17	Behringwerke Ag	Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
AU3178993A (en)	1991-11-25	1993-06-28	Enzon, Inc.	Multivalent antigen-binding proteins
AU740284B2 (en) *	1997-06-13	2001-11-01	Genentech Inc.	Stabilized antibody formulation
PT1491208E (pt) *	1999-10-04	2010-05-12	Novartis Vaccines & Diagnostic	Composições farmacêuticas contendo polipéptido líquidas estabilizadas
US7754208B2 (en)	2001-01-17	2010-07-13	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
CN101914158A (zh)	2002-02-14	2010-12-15	免疫医疗公司	抗cd 20抗体及其融合蛋白和使用方法
AU2003219958B2 (en) *	2002-02-27	2006-01-05	Immunex Corporation	Polypeptide formulation
CA2490423A1 (en) *	2002-06-21	2003-12-31	Biogen Idec Inc.	Buffered formulations for concentrating antibodies and methods of use thereof
MXPA05004022A (es)	2002-10-17	2005-10-05	Genmab As	Anticuerpos monoclonales humanos contra cd20.
WO2004058797A2 (en) *	2002-12-16	2004-07-15	Medarex, Inc.	Human monoclonal antibodies against interleukin 8 (il-8)
US8084582B2 (en) *	2003-03-03	2011-12-27	Xencor, Inc.	Optimized anti-CD20 monoclonal antibodies having Fc variants
AR044388A1 (es)	2003-05-20	2005-09-07	Applied Molecular Evolution	Moleculas de union a cd20
US7850962B2 (en)	2004-04-20	2010-12-14	Genmab A/S	Human monoclonal antibodies against CD20
DOP2006000029A (es) *	2005-02-07	2006-08-15	Genentech Inc	Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
US20090238820A1 (en) *	2005-03-08	2009-09-24	Allan Corey M	ANTI-MAdCAM ANTIBODY COMPOSITIONS
EP1942939B2 (en) *	2005-09-30	2021-07-07	Medimmune Limited	Interleukin-13 antibody composition
UA107557C2 (xx) *	2007-07-06	2015-01-26		Композиція антитіла офатумумабу
US20100189721A1 (en) *	2007-07-06	2010-07-29	Smithkline Beecham Corporation	Antibody formulations

2008
- 2008-03-07 UA UAA201001165A patent/UA107557C2/ru unknown
- 2008-07-03 PL PL15155712T patent/PL2889310T3/pl unknown
- 2008-07-03 EP EP08781323.4A patent/EP2170388B1/en active Active
- 2008-07-03 ES ES08781323.4T patent/ES2610821T3/es active Active
- 2008-07-03 ES ES15155712.1T patent/ES2663504T3/es active Active
- 2008-07-03 JO JOP/2008/0312A patent/JO3219B1/ar active
- 2008-07-03 EP EP15155712.1A patent/EP2889310B1/en active Active
- 2008-07-03 US US12/667,890 patent/US20110020328A1/en not_active Abandoned
- 2008-07-03 NO NO15155712A patent/NO2889310T3/no unknown
- 2008-07-03 KR KR1020157019741A patent/KR101670454B1/ko active Active
- 2008-07-03 CA CA2692681A patent/CA2692681C/en active Active
- 2008-07-03 WO PCT/US2008/069125 patent/WO2009009407A1/en active Application Filing
- 2008-07-03 LT LTEP15155712.1T patent/LT2889310T/lt unknown
- 2008-07-03 LT LTEP08781323.4T patent/LT2170388T/lt unknown
- 2008-07-03 TR TR2018/02928T patent/TR201802928T4/tr unknown
- 2008-07-03 HU HUE15155712A patent/HUE038501T2/hu unknown
- 2008-07-03 DK DK08781323.4T patent/DK2170388T3/en active
- 2008-07-03 SI SI200831738A patent/SI2170388T1/sl unknown
- 2008-07-03 CN CN200880105866.1A patent/CN101820912B/zh active Active
- 2008-07-03 NZ NZ582250A patent/NZ582250A/en unknown
- 2008-07-03 DK DK15155712.1T patent/DK2889310T3/en active
- 2008-07-03 KR KR1020107000148A patent/KR20100038092A/ko not_active Withdrawn
- 2008-07-03 EA EA201070105A patent/EA017994B1/ru not_active IP Right Cessation
- 2008-07-03 SI SI200831928T patent/SI2889310T1/en unknown
- 2008-07-03 AU AU2008275278A patent/AU2008275278B2/en active Active
- 2008-07-03 PT PT151557121T patent/PT2889310T/pt unknown
- 2008-07-03 HU HUE08781323A patent/HUE031288T2/hu unknown
- 2008-07-03 BR BR122020026978-2A patent/BR122020026978B1/pt active IP Right Grant
- 2008-07-03 PL PL08781323T patent/PL2170388T3/pl unknown
- 2008-07-03 PT PT87813234T patent/PT2170388T/pt unknown
- 2008-07-03 BR BRPI0814003-0A patent/BRPI0814003B1/pt active IP Right Grant
- 2008-07-03 JP JP2010516158A patent/JP5529017B2/ja active Active
- 2008-07-03 MX MX2010000017A patent/MX2010000017A/es active IP Right Grant
- 2008-07-04 TW TW097125246A patent/TWI515204B/zh active
- 2008-07-04 UY UY31210A patent/UY31210A1/es not_active Application Discontinuation
- 2008-07-04 CL CL2008001984A patent/CL2008001984A1/es unknown
- 2008-07-04 AR ARP080102910A patent/AR067455A1/es unknown
- 2008-07-04 PE PE2008001136A patent/PE20090738A1/es active IP Right Grant
- 2008-07-04 TW TW104128324A patent/TWI612060B/zh active
2009
- 2009-12-21 ZA ZA2009/09107A patent/ZA200909107B/en unknown
- 2009-12-24 IL IL202950A patent/IL202950A/en active IP Right Grant
- 2009-12-30 CO CO09149371A patent/CO6270340A2/es active IP Right Grant
- 2009-12-30 MA MA32460A patent/MA31471B1/fr unknown
2010
- 2010-01-05 DO DO2010000001A patent/DOP2010000001A/es unknown
- 2010-02-02 CR CR11249A patent/CR11249A/es unknown
- 2010-09-02 HK HK10108319.5A patent/HK1141979A1/zh unknown
- 2010-09-02 HK HK15108178.0A patent/HK1207652A1/xx unknown
2015
- 2015-02-19 US US14/625,881 patent/US20150158951A1/en not_active Abandoned
2017
- 2017-01-10 HR HRP20170033TT patent/HRP20170033T1/hr unknown
- 2017-01-12 CY CY20171100043T patent/CY1118419T1/el unknown
- 2017-08-29 AR ARP170102392A patent/AR109461A2/es not_active Application Discontinuation
2018
- 2018-03-14 HR HRP20180440TT patent/HRP20180440T1/hr unknown
- 2018-03-20 CY CY20181100325T patent/CY1120047T1/el unknown
2021
- 2021-09-13 NO NO2021036C patent/NO2021036I1/no unknown
- 2021-09-14 CY CY2021027C patent/CY2021027I2/el unknown
- 2021-09-14 FR FR21C1040C patent/FR21C1040I1/fr active Active
- 2021-09-15 HU HUS2100038C patent/HUS2100038I1/hu unknown
- 2021-09-15 LT LTPA2021520C patent/LTPA2021520I1/lt unknown

Also Published As

Publication number	Publication date
WO2009009407A1 (en)	2009-01-15
UA107557C2 (xx)	2015-01-26
TR201802928T4 (tr)	2018-03-21
EP2889310B1 (en)	2017-12-20
NO2889310T3 (no)	2018-05-19
HUE038501T2 (hu)	2018-10-29
EA201070105A1 (ru)	2010-08-30
PE20090738A1 (es)	2009-07-18
HK1141979A1 (zh)	2010-11-26
EA017994B1 (ru)	2013-04-30
KR20100038092A (ko)	2010-04-12
CY2021027I1 (el)	2021-12-31
CN101820912A (zh)	2010-09-01
TW200914466A (en)	2009-04-01
FR21C1040I1 (fr)	2021-11-19
JP5529017B2 (ja)	2014-06-25
AU2008275278B2 (en)	2011-04-14
EP2170388A4 (en)	2011-07-06
HK1207652A1 (en)	2016-02-19
ES2663504T3 (es)	2018-04-13
LT2170388T (lt)	2017-01-10
CA2692681C (en)	2018-12-04
BRPI0814003B1 (pt)	2021-06-15
EP2889310A1 (en)	2015-07-01
NZ582250A (en)	2012-04-27
HUS2100038I1 (hu)	2021-10-28
CY1118419T1 (el)	2017-06-28
BR122020026978B1 (pt)	2021-09-28
HUE031288T2 (hu)	2017-06-28
AR067455A1 (es)	2009-10-14
HRP20170033T1 (hr)	2017-03-24
PT2889310T (pt)	2018-03-26
PT2170388T (pt)	2017-01-04
CY2021027I2 (el)	2021-12-31
CL2008001984A1 (es)	2009-01-09
US20110020328A1 (en)	2011-01-27
ES2610821T3 (es)	2017-05-03
MA31471B1 (fr)	2010-06-01
SI2170388T1 (sl)	2017-01-31
IL202950A0 (en)	2011-08-01
SI2889310T1 (en)	2018-04-30
DK2170388T3 (en)	2017-01-16
EP2170388A1 (en)	2010-04-07
AU2008275278A1 (en)	2009-01-15
IL202950A (en)	2014-05-28
CO6270340A2 (es)	2011-04-20
TWI515204B (zh)	2016-01-01
PL2170388T3 (pl)	2017-06-30
LTPA2021520I1 (no)	2021-10-11
MX2010000017A (es)	2010-04-07
CN101820912B (zh)	2014-03-12
HRP20180440T1 (hr)	2018-04-20
EP2170388B1 (en)	2016-10-12
KR20150088335A (ko)	2015-07-31
UY31210A1 (es)	2009-01-30
CR11249A (es)	2010-03-08
PL2889310T3 (pl)	2018-06-29
KR101670454B1 (ko)	2016-10-31
JO3219B1 (ar)	2018-03-08
LT2889310T (lt)	2018-03-26
CA2692681A1 (en)	2009-01-15
TW201623334A (zh)	2016-07-01
JP2011526880A (ja)	2011-10-20
TWI612060B (zh)	2018-01-21
ZA200909107B (en)	2012-12-27
BRPI0814003A2 (pt)	2015-02-03
CY1120047T1 (el)	2018-12-12
US20150158951A1 (en)	2015-06-11
AR109461A2 (es)	2018-12-12
DOP2010000001A (es)	2010-01-31
DK2889310T3 (en)	2018-03-26

Publication	Publication Date	Title
NO2021036I1 (no)	2021-09-13	Ofatumumab
DE602008006301D1 (de)	2011-06-01	Koaxialnadelanordnung
BRPI0821573A2 (pt)	2016-08-09	benzofuropirimidonas
ATE501136T1 (de)	2011-03-15	Imidazopyridinone
DE502007001207D1 (de)	2009-09-10	Elektrosaugkopf
ATE514696T1 (de)	2011-07-15	Diphenyl-dihydro-imidazopyridinone
DE602008002772D1 (de)	2010-11-11	Polyvinylpyrrolidonpulverzusammensetzungen
DE112008003636A5 (de)	2010-10-21	Mehrzuggruppierer
BRPI0814519A2 (pt)	2014-09-30	Organopolissiloxano
BRPI0811451A2 (pt)	2014-11-04	Exopolissacarídeo
DE602008000923D1 (de)	2010-05-20	Einzelwaferätzgerät
DE602008000749D1 (de)	2010-04-15	Buschschneider
BRPI0812840A2 (pt)	2014-12-09	2-imidazolinas
BRPI0815547A2 (pt)	2015-02-10	Depsipeptídeos cícliocos
BRPI0812994A2 (pt)	2014-12-23	Microbiocidas
AT505058A3 (de)	2008-12-15	Türschliesssystem
DE602008001234D1 (de)	2010-06-24	Bandmaterialzuführvorrichtung
DE602008004695D1 (de)	2011-03-10	Katalysatorträgerwabe
EP2195521A4 (en)	2015-09-30	Fuel vapor separator
DE602008005950D1 (de)	2011-05-19	Münzvereinzeler
DE112008001216A5 (de)	2010-02-04	Magnetronplasmaanlage
DE502008001694D1 (de)	2010-12-16	Mitfahrhubwagen
DE112008003094A5 (de)	2010-08-12	Geomatte
DE602008001674D1 (de)	2010-08-19	Wimpernwickler
DE112008003196A5 (de)	2011-02-03	Handpipettiergerät